oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
Örebro universitet, Institutionen för hälsovetenskap och medicin. Region Örebro län. Department of Obstetrics and Gynecology.
Örebro universitet, Institutionen för hälsovetenskap och medicin. Region Örebro län. Department of Obstetrics and Gynecology.
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Vise andre og tillknytning
2013 (engelsk)Inngår i: Menopause: The Journal of the North American Menopause, ISSN 1072-3714, E-ISSN 1530-0374, Vol. 20, nr 2, s. 162-168Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

Methods: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

Results: In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitorYtreated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

Conclusions: Our findings suggest that sexual dysfunction in aromatase inhibitorYtreated women is a greatly underestimated problem.

sted, utgiver, år, opplag, sider
Lippincott Williams & Wilkins, 2013. Vol. 20, nr 2, s. 162-168
Emneord [en]
Aromatase inhibitors, Breast cancer, Postmenopausal women, Sexual dysfunction, Tamoxifen
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-54872DOI: 10.1097/gme.0b013e31826560daISI: 000314342600010PubMedID: 22990756Scopus ID: 2-s2.0-84873409411OAI: oai:DiVA.org:oru-54872DiVA, id: diva2:1066943
Forskningsfinansiär
Swedish Cancer Society, CAN 2009/773Swedish Research Council, VR 621-2008-3562
Merknad

Funding Agency:

Uppsala-Örebro Regional Research Council 

Lions Clubs International 

Percy Falk Foundation 

Tilgjengelig fra: 2017-01-19 Laget: 2017-01-19 Sist oppdatert: 2018-01-13bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Baumgart, JulianeNilsson, Kerstin

Søk i DiVA

Av forfatter/redaktør
Baumgart, JulianeNilsson, Kerstin
Av organisasjonen
I samme tidsskrift
Menopause: The Journal of the North American Menopause

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 210 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf